The migraine field is currently in ‘an exciting era of new treatments’, says Zaza Katsarava, MD, PhD, MSc, University of Essen, Essen, Germany. Historically, repurposed drugs were the only treatment options available for patients with migraine. Recent years have seen huge growth in the number of agents available that have been designed specifically for migraine based on known underlying pathogenic mechanisms. While calcitonin gene-related peptide (CGRP) pathway-targeting agents have enabled us to break into the migraine-specific space, Prof. Katsarava highlights that there is much more to come, with new agents and novel targets on the horizon. This interview took place during the European Academy of Neurology 2021 congress.

свернуть